Результати пошуку - Francesco Schettini

Уточнити результати
  1. 1
    Dissecting the biological heterogeneity of HER2-positive breast cancer

    Dissecting the biological heterogeneity of HER2-positive breast cancer за авторством Francesco Schettini, Aleix Prat

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes

    A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes за авторством Francesco Schettini, Fara Brasó‐Maristany, Nicole M. Kuderer, Aleix Prat

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer

    Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer за авторством Claudette Falato, Francesco Schettini, Tomás Pascual, Fara Brasó‐Maristany, Aleix Prat

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  4. 4
    Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going

    Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going за авторством Francesco Schettini, Giuseppe Buono, Cinzia Cardalesi, Isacco Desideri, Sabino De Placido, Lucia Del Mastro

    Опубліковано 2016
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  5. 5
    Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment

    Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment за авторством Caterina Gianni, Michela Palleschi, Giuseppe Schepisi, Chiara Casadei, Sara Bleve, Filippo Merloni, Marianna Sirico, Samanta Sarti, Lorenzo Cecconetto, Giandomenico Di Menna, Francesco Schettini, Ugo De Giorgi

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  6. 6
    The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients

    The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients за авторством Adriana Ceci, Paola Baiardi, Mariagrazia Felisi, Maria Domenica Cappellini, V. Carnelli, Vincenzo De Sanctis, Renzo Galanello, Aurelio Maggio, Giuseppe Masera, Antonio Piga, Francesco Schettini, Ippazio Stefàno, Fernando Tricta

    Опубліковано 2002
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

    CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors за авторством Francesco Schettini, Irene De Santo, Carmen G. Rea, Pietro De Placido, Luigi Formisano, Mario Giuliano, Grazia Arpino, Michelino De Laurentiis, Fabio Puglisi, Sabino De Placido, Lucia Del Mastro

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  8. 8
    Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis

    Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis за авторством Chiara Molinelli, Flavia Jacobs, Elisa Agostinetto, Guilherme Nader Marta, Marcello Ceppi, Marco Bruzzone, Eva Blondeaux, Francesco Schettini, Aleix Prat, Giuseppe Viale, Lucia Del Mastro, Matteo Lambertini, Evandro de Azambuja

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  9. 9
    CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial

    CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial за авторством Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó‐Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review

    Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case re... за авторством Javier Muñoz, Sabrina Nucera, Natalia García, Isaac Cebrecos, G. Osés, Sergi Ganau, Esther Sanfeliu, Pedro Jares, Mercedes Marín‐Aguilera, Patricia Galván, Fara Brasó‐Maristany, Olga Martínez‐Sáez, Enric Cascos, Carme Font, Francesco Schettini

    Опубліковано 2025
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  11. 11
    Frequency and spectrum of PIK3CA somatic mutations in breast cancer

    Frequency and spectrum of PIK3CA somatic mutations in breast cancer за авторством Olga Martínez‐Sáez, Núria Chic, Tomás Pascual, Bárbara Adamo, María Vidal, Blanca González‐Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó‐Maristany, A. Rodríguez, Eduardo Martínez de Dueñas, Patricia Galván, Ana Belén Rodríguez, Antonio Martı́nez, Montserrat Muñoz, Aleix Prat

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis

    Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis за авторством Francesco Schettini, Fabiola Giudici, Mario Giuliano, Massimo Cristofanilli, Grazia Arpino, Lucia Del Mastro, Fabio Puglisi, Sabino De Placido, Ida Paris, Pietro De Placido, Sergio Venturini, M. De Laurentis, Pierfranco Conté, Dejan Juric, Antonio Llombart‐Cussac, Lajos Pusztai, Aleix Prat, Guy Jérusalem, Angelo Di Leo, Daniele Generali

    Опубліковано 2020
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  13. 13
    Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis

    Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis за авторством Francesco Schettini, Sabrina Nucera, Tomás Pascual, Olga Martínez‐Sáez, Rodrigo Sánchez-Bayona, Benedetta Conte, Giuseppe Buono, Matteo Lambertini, Kevin Punie, Juan Miguel Cejalvo, Grazia Arpino, Paolo Vigneri, Daniele Generali, Eva Ciruelos, Javier Cortés, Alessandra Gennari, Montserrat Muñoz, María Vidal, Sara M. Tolaney, Aleix Prat, Guillermo Villacampa

    Опубліковано 2024
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  14. 14
    23P Clinical, pathological and gene expression features of HER2-low breast cancer

    23P Clinical, pathological and gene expression features of HER2-low breast cancer за авторством Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Aranzazu Fernández-Martínez, Blanca González‐Farré, Esther Sanfeliu, Giuseppe Perrone, Patricia Villagrasa, Joaquín Gavilá Gregori, Carlos H. Barrios, Aña Lluch, M. Martín Jiménez, Sabino De Placido, Aleix Prat

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

    Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study за авторством Giuseppe Buono, Anna Crispo, Mario Giuliano, Carmine De Angelis, Francesco Schettini, Valeria Forestieri, Rossella Lauria, Michelino De Laurentiis, Pietro De Placido, Carmen G. Rea, Carmen Pacilio, Emanuela Esposito, Maria Grimaldi, Flavia Nocerino, Giuseppe Porciello, Aldo Giudice, Alfonso Amore, Anita Minopoli, Gerardo Botti, Sabino De Placido, Meghana V. Trivedi, Grazia Arpino

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Gene expression profiles of breast cancer metastasis according to organ site

    Gene expression profiles of breast cancer metastasis according to organ site за авторством Fara Brasó‐Maristany, Laia Paré, Núria Chic, Olga Martínez‐Sáez, Tomás Pascual, Meritxell Mallafré‐Larrosa, Francesco Schettini, Blanca González‐Farré, Esther Sanfeliu, Eduardo Martínez de Dueñas, Patricia Galván, Esther Barnadas, Belinda Salinas, Pablo Tolosa, Eva Ciruelos, Esther Carcelero, Cecilia Guillén, Bárbara Adamo, Reinaldo Moreno, María Vidal, Montserrat Muñoz, Aleix Prat

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

    A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies за авторством Benedetta Conte, Fara Brasó‐Maristany, A. Rodríguez, Tomás Pascual, Guillermo Villacampa, Francesco Schettini, María Vidal, Elia Seguí, Laura Angelats, Isabel García-Fructuoso, Raquel Gómez Bravo, Natàlia Lorman-Carbó, Laia Paré, Mercedes Marín‐Aguilera, Olga Martínez‐Sáez, Bárbara Adamo, Esther Sanfeliu, Beatrice Fratini, Claudette Falato, Núria Chic, Ana Vivancos, Patricia Villagrasa, Johan Staaf, Joel S. Parker, Charles M. Perou, Aleix Prat

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

    Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer за авторством Francesco Schettini, S. Nucera, F Brasó-Maristany, Irene De Santo, T. Pascual, M. Bergamino, P. Galván, B. Conte, E. Seguí, I. García Fructuoso, R. Gómez Bravo, P. Rivera, A.B. Rodríguez, O. Martínez-Sáez, S. Ganau, E. Sanfeliu, B. González-Farre, María Vidal, B. Adamo, I. Cebrecos, E. Mension, G. Oses, P. Jares, S. Vidal-Sicart, M. Mollà, Montserrat Muñoz, A. Prat

    Опубліковано 2024
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer за авторством Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Esther Barnadas, Aranzazu Fernández-Martínez, Blanca González‐Farré, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Aña Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer за авторством Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Esther Barnadas, Aranzazu Fernández-Martínez, Blanca González‐Farré, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Aña Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Errata/Corrigenda
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: